Under the Radar: Summit Shares Sink After FDA Rejects Lung Cancer Drug — WSJ
By Xavier MartinezShares of Summit Therapeutics fell about 15% Monday after the company said the Food and Drug Administration had rejected its experimental lung cancer drug ivonescimab.The immunotherapy, developed by Chinese drugmaker Akeso and licensed by Summit, targets two proteins: one that hel…